Improved Outcomes with Low-Dose Hypomethylating Agent Plus Venetoclax As Post-Transplant Maintenance in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies

Key Points

• Improved outcomes in patients with myeloid malignancies receiving low-dose hypomethylating agents with venetoclax post-transplant.
• A notable 30% reduction in relapse rates was observed among treated patients compared to historical controls.
• Assessment of treatment effectiveness employed a retrospective cohort analysis of post-transplant outcomes.
• Highlights the importance of innovative maintenance therapies in enhancing survival after hematopoietic stem cell transplantation.